Most people with SCD seem to meet or exceed current level of physical activity recommendations for the general population, a ...

Columnist Oluwatosin Adesoye shares her thoughts about the role of World Sickle Cell Day in promoting sickle cell awareness.

BEAM-101, a treatment for sickle cell disease, showed sustained efficacy and safety over one year in the BEACON Phase 1/2 ...

Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela ...

The BEACON trial (NCT05456880), which began dosing last year, is evaluating the safety and efficacy of BEAM-101 in people with severe SCD, ages 18-35, who have had at least four VOCs in the two years ...